Dr. Alvarez-Secord explains that unlike FR-alpha or HER2 ADCs that target growth signals, B7-H4 is embedded in immune regulation. Administering a B7-H4 ADC relieves microenvironment immunosuppression while tumor cell kill releases neoantigens, creating synergy when paired with checkpoint inhibitors like dostarlimab.
Proactive management of topoisomerase-1 ADC payload toxicities requires upgrading antiemetic regimens by adding neurokinin-1 inhibitors such as aprepitant to standard ondansetron and dexamethasone. Dr. Alvarez-Secord also utilizes upfront growth factor support for at-risk patients and prompt anti-motility treatment to prevent dose interruptions.
Clinical experience demonstrates that patients progressing on targeted agents can still respond to ADCs directed against the identical target if the mechanism or payload is switched. However, phase 3 clinical trial exclusions for prior topoisomerase-1 ADC exposure currently restrict the generation of sequencing data.
Patients whose endometrial cancer progresses after frontline platinum-based chemotherapy and checkpoint inhibition face a major treatment gap. Data from the Blue Star study showed the ADC PuxiSAM achieved confirmed overall response rates above 60% across cohorts, specifically including this previously treated post-IO population.
Unlike targets like FR-alpha and HER2 that require high expression thresholds to yield significant clinical responses, B7-H4 exhibits expression rates between 80% and 90% across ovarian and endometrial cancers. This pervasive prevalence may allow broader patient eligibility without requiring restrictive biomarker cutoffs.
